Navigation Links
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
Date:5/13/2008

ey're taking NovoSeven(R) may be at increased risk for thrombosis. Serious adverse events which may or may not have been related to the use of NovoSeven(R) occurred in 14 of the 298 patients in the initial clinical program. There have been no reports of NovoSeven(R) causing bad reactions to "analgesics" (such as pain killers), "antibiotics" (the drugs used to treat infection), or "sedatives" (sleeping pills or tranquilizers). Development of antibodies against Factor VII has been reported in Factor VII-deficient patients after treatment with NovoSeven(R). These patients had previously been treated with human plasma and/or plasma-derived Factor VII.

About Novo Nordisk

Novo Nordisk is a health care company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone replacement therapy.

Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Media

Sean Clements

Novo Nordisk

PH: (609) 514-8316


'/>"/>
SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis
2. FDA Approves Health Claim for Brown Rice
3. FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents
4. FDA approves HeartMate II mechanical heart pump for heart-failure patients
5. FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
6. FDA Approves New Once-a-Month Dose of Actonel for Postmenopausal Osteoporosis
7. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
8. FDA APPROVES ROTARIX(R) [Rotavirus Vaccine, live, oral], THE FIRST VACCINE LICENSED TO COMPLETE THE ROTAVIRUS IMMUNIZATION SERIES BY FOUR MONTHS OF AGE
9. House Overwhelmingly Approves Renewal and Tripling of Successful U.S. Global AIDS Prevention Effort
10. VeriPrime Approves New Best Practices for Beef Production
11. U.S. EPA Approves Registration of Antimicrobial Copper Alloys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... to receive at least if you,re an adolescent and ... found that 15- and 16-year-olds who find pleasure in pro-social ... less likely to become depressed than those who get a ... themselves. , The researchers detail their findings in the ... study focused on the ventral striatum, a brain region that ...
(Date:4/24/2014)... Ore. An Oregon State University researcher has found ... of the symptoms of autism spectrum disorder in very ... be the first to show a direct relationship between ... fine and gross motor skills should be included in ... MacDonald, an assistant professor in OSU,s College of Public ...
(Date:4/24/2014)... led by a scientist at the University of York ... in the development of the nervous system may also ... cancer., A research team, led by Dr Will ... of Biology at York, has studied how voltage-gated sodium ... channels are found in the membranes of excitable cells, ...
(Date:4/23/2014)... immigrants from Sub-Saharan Africa, Latin America and Caribbean ... to new research from St. Michael,s Hospital. , ... Journal of Obstetrics and Gynaecology , assessed the ... and native-born women in six high-immigration countries ... and Valencia) and the United States (California, New ...
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
... Laboratories, L.P.,today announced that the U.S. Food and Drug ... vitamin D3 product for the,treatment of mild-to-moderate plaque psoriasis ... a chronic skin disorder that affects 2 to 3 ... red, scaly patches of skin and,caused by an abnormally ...
... To mark American Heart,Month, deCODE genetics (Nasdaq: DCGN ... will offer its deCODEme Cardio Scan(TM), the unique new ... of heart,attack, stroke and atrial fibrillation, intracranial and abdominal ... of,$100. , On Thursday, February ...
... 3 NxStage Medical, Inc. (Nasdaq: NXTM ), ... to release its financial results for the fourth quarter and ... 2009 before the opening of the financial markets.NxStage will also ... Thursday, March 12, 2009 to discuss its fourth quarter and ...
... 3 The Albert and Mary Lasker Foundation ... , the immediate past director of the National Institutes of ... Directors."We are delighted that Dr. Zerhouni has agreed to join ... , President of the Lasker Foundation. "The Lasker Foundation is ...
... to Chief Marketing Officer and PACS Industry Veteran ... ManagerWASHINGTON, Feb. 3 Compressus, Inc., leaders in ... team with the promotion of Janine Broda to ... Shawn Gibbons as vice president and general manager ...
... The Female Health Company (NYSE Alternext: FHC) today ... to discuss its operating results for the first quarter ... Tuesday, February 10, 2009. The Company plans to ... day. Shareholders and other interested parties may participate in ...
Cached Medicine News:Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 2Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 3Health News:Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis 4Health News:deCODEme(TM) Takes on Heart Disease in February 2Health News:deCODEme(TM) Takes on Heart Disease in February 3Health News:deCODEme(TM) Takes on Heart Disease in February 4Health News:deCODEme(TM) Takes on Heart Disease in February 5Health News:NxStage to Report Fourth Quarter and Full Year 2008 Financial Results 2Health News:Lasker Foundation Welcomes Elias Zerhouni to Board of Directors 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... February 23 An international team of,researchers ... for,osteoarthritis of the knee, and the results ... the specialist journal "Osteoarthritis and Cartilage".,The researchers ... of,various osteoarthritis treatments. After six months as ...
... Encouraging Safety and Efficacy Results Support Follow-on NEST-3 ... trial sponsored by PhotoThera, Inc., transcranial laser therapy ... of stroke onset demonstrated improved outcomes for patients, ... A post-hoc analysis in patients who had ...
Cached Medicine Technology:New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years 2Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: